Arginine-free diet with chemoradiation before rectal cancer surgery
Part of Cancer, Digestive system clinical trials.
This trial tests whether avoiding arginine (a protein building block) in the diet during chemoradiation can make the tumor shrink more before surgery for locally advanced rectal cancer. It may help reduce side effects and improve surgical outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have rectal cancer that is locally advanced (stage cT3, cT4, or node-positive) but has not spread to distant organs.
- You are generally able to care for yourself (ECOG 0-1).
- You can eat or receive nutrition through a feeding tube.
- Your blood tests show adequate organ function (e.g., normal kidney, liver, and blood counts).
- If you can become pregnant, you agree to use reliable birth control during and after the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a specific “before surgery” treatment (radiation plus chemotherapy), followed by more chemotherapy to improve outcomes in people with certain types of rectal cancer. You might be considered if your cancer is locally advanced but not spread to distant organs.
This Phase 2 study tests whether a shorter course of radiation, combined with chemotherapy (CAPOX) and an immunotherapy drug (tislelizumab), can control middle and low rectal cancer. It may also help people who strongly want to keep their anus, if the cancer and overall health fit the study rules.
This trial tests whether adding leucine (a simple amino acid) to standard chemoradiation before surgery can help shrink rectal cancer and improve outcomes. It is for people with locally advanced rectal cancer that hasn't yet spread to other organs.
This trial tests a combination of chemotherapy and an immunotherapy drug (a PD-1 inhibitor) given before surgery for locally advanced rectal cancer. The goal is to see if this approach can improve outcomes compared to standard treatment.
This study tests a combination of a special diet supplement (beta-hydroxybutyrate), short radiation therapy, immunotherapy, and chemotherapy before surgery for locally advanced rectal cancer. The goal is to see if this approach helps shrink the tumor and improve treatment outcomes.
This trial tests a combination of brief radiation therapy, two chemotherapy drugs (nal-IRI and capecitabine), and an immunotherapy drug (camrelizumab) for locally advanced rectal cancer. The goal is to shrink the tumor and improve outcomes before surgery.
Hear when a new Rectal Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.